Detail akcie Macrogenics online

Business Summary: MacroGenics, Inc. is a biopharmaceutical company focused on developing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. It generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is developing product candidates that target various tumor-associated antigens and immune checkpoint molecules. Its lead pipeline program is vobramitamab duocarmazine (vobra duo), an antibody-drug conjugate (ADC) that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. Its clinical pipeline includes two product candidates based on its, bispecific DART technology that co-engages both PD-1 and other checkpoint molecules. These candidates include lorigerlimab and tebotelimab. In addition, it is developing MGD024, a bispecific DART molecule. It is also developing various other programs.
Financial Summary: BRIEF: For the six months ended 30 June 2024, MacroGenics Inc revenues decreased 47% to $19.9M. Net loss totaled $107.9M vs. income of $19.5M. Revenues reflect Collaborative and other agreements decrease of 85% to $3.5M, Royalty revenue decrease of 39% to $258K, Contract manufacturing decrease of 1% to $5.2M. Net loss reflects Gain on modification of debt decrease from $100.9M (income) to $0K.